Table 2.
Cohort treatment outline, CAR T cell dose and patient outcome
| Cohort | Patient number | Chemotherapy administered | No of IL2 infusionsa | Cohort dose (total T cells per patient) | Actual Dose of viable T cell product (×1010) | MFEζ Transgene expression (%) | Total dose of viable MFEζ T cells administered (×109) | Best tumour responseb |
|---|---|---|---|---|---|---|---|---|
| 1 | 36003 | F | 7 | 109 | 0.10 | 21.3 | 0.21 | SD (150) |
| 36004 | F | 12 | 0.10 | 21.4 | 0.21 | SD (108) | ||
| 36005 | F | 11 | 0.10 | 22.1 | 0.22 | PD | ||
| 2 | 36006 | F | 5 | 1010 | 0.97 | 27.3 | 2.64 | SD (83) |
| 36007 | F | 3 | 0.41 | 33.7 | 1.38 | PD | ||
| 36008 | F | 3 | 1.00 | 26.4 | 2.64 | PD | ||
| 36009 | F | 8 | 1.00 | 24.5 | 2.45 | PDc | ||
| 3 | 36010 | F | 3 | 109 – 5 × 1010 | 1.01 | 20.1 | 2.03 | SD (88) |
| 36011 | F | 2 | 1.21 | 23.6 | 2.86 | PD | ||
| 36012 | F | 5 | 0.98 | 34.9 | 3.43 | PD | ||
| 4 | 36013 | F + C | 7 | 109 – 5 × 1010 | 0.90 | 37.3 | 3.36 | SD (84) |
| 36014 | F + C | 3 | 1.32 | 29.4 | 3.89 | SD (155) | ||
| 36015 | F + C | 5 | 0.68 | 36.4 | 2.48 | SD (119) | ||
| 36017 | F + C | 10 | 0.17 | 20.1 | 0.33 | PD |
F fludarabine 25 mg/m2/day for 5 days, C cyclophosphamide 60 mg/kg/day for 2 days
aIntravenous bolus IL-2; 600,000 IU/kg per dose
bThe duration of stable disease (SD) has been estimated from the pre-treatment scan date to the most recent scan on study. Progressive disease as assessed at week 6 scan
cClinical progression (patient unfit for CT restaging scan)